An optical coherence tomography study of two new generation stents with 2 biodegradable polymer carrier, eluting paclitaxel vs. biolimus-A9

Το τεκμήριο παρέχεται από τον φορέα :
Πανεπιστήμιο Πατρών   

Αποθετήριο :
Νημερτής   

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



An optical coherence tomography study of two new generation stents with 2 biodegradable polymer carrier, eluting paclitaxel vs. biolimus-A9 (EL)

Tsigkas, Grigorios
Mavronasiou, Eleni
Alexopoulos, Dimitrios
Davlouros, Periklis
Xanthopoulou, Ioanna
Karantalis, Vasileios
Hahalis, George

Χαλάλης, Γεώργιος
Μαυρονάσιου, Ελένη
Τσίγκας, Γρηγόριος
Ξανθοπούλου, Ιωάννα
Δαβλούρος, Περικλής
Καρανταλής, Βασίλειος
Αλεξόπουλος, Δημήτριος

Journal (paper) (EL)

2019-02-01T19:09:48Z
2011-11


-- (EL)
Background: Tissue coverage and strut apposition of drug eluting stents (DES), which can be assessed with 21 optical coherence tomography (OCT), may be associated with late stent thrombosis (LST). 22 Methods: Prospective observational angiographic and OCT follow-up at 6 months post-implantation of a 23 biolimus-A9 eluting stent (BES) vs. a paclitaxel eluting stent (PES), with biodegradable polymer carriers. The 24 primary outcome was the percent difference of uncovered struts between BESs and PESs. 25 Results: A maximum likelihood model was used for analysis, to account for data clustering. Sixteen patients 26 were treated with BES (28 lesions/4530 struts) and 16 with PES (23 lesions/4450 struts). Overall, BESs 27 compared to PESs had more uncovered [0.41% vs. 0.21%, difference estimate (DE) 0.2 (95% CI, 0.06–0.34), 28 p=0.006], malapposed [0.18% vs. 0.04%, DE 0.14 (95% CI 0.05–0.23), p=0.003], uncovered and malapposed 29 [0.08% vs. 0.026%, DE 0.057 (95% CI 0.015–0.1), p=0.01] and protruding struts [0.23% vs. 0.04%, DE 0.185 (95% 30 CI 0.1–0.27), pb0.001], and significantly lower neointimal thickness (59.3± 28.2 μm vs. 201.7± 97.5, 31 pb0.001). None of the BESs was totally covered with neointima, in contrast to 5 (21.7%) PESs (p=0.01). 32 Thrombus was detected in 1 (3.6%) BES and 5 (21.7%) PESs (p=0.05); however, no patient experienced 33 clinical stent thrombosis. 34 Conclusion: Between two stents with biodegradable polymer, OCT demonstrated that BESs had more 35 uncovered and malapposed struts compared to PESs at 6 months. This difference might be partly attributed to 36 the more potent antiproliferative properties of biolimus-A9; however, its impact on clinical outcome and on 37 the risk of LST is yet to be determined. (EL)


Paclitaxel (EL)
Neointimal coverage (EL)
Biolimus-A9 (EL)
Malapposition (EL)
Optical coherence tomography (OCT) (EL)
Πακλιταξέλη (EL)
Οπτική τομογραφία συνοχής (EL)





*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.